Sunitinib malate, a receptor tyrosine kinase inhibitor, is effective in the treatment of restrictive heart failure due to heart metastases from renal cell carcinoma.

@article{Szmit2009SunitinibMA,
  title={Sunitinib malate, a receptor tyrosine kinase inhibitor, is effective in the treatment of restrictive heart failure due to heart metastases from renal cell carcinoma.},
  author={Sebastian Szmit and Magdalena Zagrodzka and Marcin Kurzyna and Grzegorz Opolski and Cezary A. Szczylik},
  journal={Cardiology},
  year={2009},
  volume={114 1},
  pages={
          67-71
        }
}
Few systematic trials have studied metastatic tumors to the heart and there are currently no guidelines for the treatment of heart metastases and its associated symptoms. This article presents the first known case of effective pharmacological treatment of heart failure due to metastases of renal cell carcinoma (RCC). Due to pressure caused by metastatic tissue on the left atrium and the decreased blood inflow to the left ventricle, the 61-year-old male patient suffered from dyspnea. Treatment… CONTINUE READING
BETA

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 15 REFERENCES

Metastatic renal cell carcinoma to right ventricle without vena caval involvement.

  • International journal of urology : official journal of the Japanese Urological Association
  • 2008

Renal cell carcinoma extending from superior vena cava into right atrium.

  • Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
  • 2007